Tryptamine Therapeutics (AU:TYP) has released an update.
Tryptamine Therapeutics has reported groundbreaking results from its Phase 2a clinical trial, revealing that 100% of fibromyalgia patients experienced pain reduction after treatment with its oral psilocybin formulation, TRP-8802, combined with psychotherapy. These findings, presented at the IASP 2024 World Congress on Pain, show significant potential for psychedelic-assisted therapy in treating fibromyalgia, a condition with limited current treatments. The success of the trial not only validates the company’s clinical approach but also enhances its intellectual property portfolio, with plans to commence a Phase 2 trial of TRP-8803 in the first half of 2025.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.